# Pliant Therapeutics, Inc.: financial statements, quarterly

PLRX · Nasdaq · CIK 1746473 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/plrx.md) · [Financials](/companies/plrx/financials.md) · [Filings](/companies/plrx/filings.md) · [Insiders](/companies/plrx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/plrx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001746473-24-000171.md) | [0.0 d](/filings/0001746473-25-000054.md) | [0.0](/filings/0001746473-24-000076.md) | [0.0](/filings/0001746473-24-000145.md) | [0.0](/filings/0001746473-24-000171.md) | [0.0 d](/filings/0001746473-26-000037.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [32.3](/filings/0001746473-24-000171.md) | [33.2 d](/filings/0001746473-25-000054.md) | [37.1](/filings/0001746473-25-000099.md) | [45.6](/filings/0001746473-25-000150.md) | [47.8](/filings/0001746473-25-000175.md) | [38.8 d](/filings/0001746473-26-000037.md) | [43.4](/filings/0001746473-26-000090.md) | [32.2](/filings/0001746473-26-000113.md) | [17.9](/filings/0001746473-25-000175.md) | [15.6 d](/filings/0001746473-26-000037.md) | [13.6](/filings/0001746473-26-000090.md) | [16.7](/filings/0001746473-26-000113.md) |
| Operating income | $m | [(47.7)](/filings/0001746473-24-000171.md) | [(47.0) d](/filings/0001746473-25-000054.md) | [(52.4)](/filings/0001746473-25-000099.md) | [(60.6)](/filings/0001746473-25-000150.md) | [(62.0)](/filings/0001746473-25-000175.md) | [(53.3) d](/filings/0001746473-26-000037.md) | [(58.9)](/filings/0001746473-26-000090.md) | [(45.6)](/filings/0001746473-26-000113.md) | [(28.3)](/filings/0001746473-25-000175.md) | [(23.6) d](/filings/0001746473-26-000037.md) | [(21.8)](/filings/0001746473-26-000090.md) | [(23.9)](/filings/0001746473-26-000113.md) |
| Interest expense | $m | [0.3](/filings/0001746473-23-000074.md) | [0.3 d](/filings/0001746473-24-000043.md) | [0.4](/filings/0001746473-24-000076.md) | [0.9](/filings/0001746473-25-000150.md) | [0.9](/filings/0001746473-25-000175.md) | [0.8 d](/filings/0001746473-26-000037.md) | [0.8](/filings/0001746473-26-000090.md) | [0.8](/filings/0001746473-26-000113.md) | [0.8](/filings/0001746473-25-000175.md) | [0.1 d](/filings/0001746473-26-000037.md) | [0.0](/filings/0001746473-26-000090.md) | [0.0](/filings/0001746473-26-000113.md) |
| Income tax | $m | [0.0](/filings/0001746473-24-000171.md) | [0.0 d](/filings/0001746473-25-000054.md) | [0.0](/filings/0001746473-25-000099.md) | [0.0](/filings/0001746473-25-000150.md) | [0.0](/filings/0001746473-25-000175.md) | [0.0 d](/filings/0001746473-26-000037.md) | [0.0](/filings/0001746473-26-000090.md) | [0.0](/filings/0001746473-26-000113.md) | [0.0](/filings/0001746473-25-000175.md) | [0.0 d](/filings/0001746473-26-000037.md) | [0.0](/filings/0001746473-26-000090.md) | [0.0](/filings/0001746473-26-000113.md) |
| Net income | $m | [(41.5)](/filings/0001746473-24-000171.md) | [(41.1) d](/filings/0001746473-25-000054.md) | [(47.0)](/filings/0001746473-25-000175.md) | [(55.9)](/filings/0001746473-25-000175.md) | [(57.8)](/filings/0001746473-25-000175.md) | [(49.7) d](/filings/0001746473-26-000037.md) | [(56.2)](/filings/0001746473-26-000113.md) | [(43.3)](/filings/0001746473-26-000113.md) | [(26.3)](/filings/0001746473-25-000175.md) | [(23.6) d](/filings/0001746473-26-000037.md) | [(20.0)](/filings/0001746473-26-000113.md) | [(22.4)](/filings/0001746473-26-000113.md) |
| Diluted EPS | $ per share | [(0.70)](/filings/0001746473-24-000171.md) | not reported | [(0.78)](/filings/0001746473-25-000099.md) | [(0.92)](/filings/0001746473-25-000150.md) | [(0.95)](/filings/0001746473-25-000175.md) | not reported | [(0.92)](/filings/0001746473-26-000090.md) | [(0.71)](/filings/0001746473-26-000113.md) | [(0.43)](/filings/0001746473-25-000175.md) | not reported | [(0.32)](/filings/0001746473-26-000090.md) | [(0.36)](/filings/0001746473-26-000113.md) |
| Basic EPS | $ per share | [(0.70)](/filings/0001746473-24-000171.md) | not reported | [(0.78)](/filings/0001746473-25-000099.md) | [(0.92)](/filings/0001746473-25-000150.md) | [(0.95)](/filings/0001746473-25-000175.md) | not reported | [(0.92)](/filings/0001746473-26-000090.md) | [(0.71)](/filings/0001746473-26-000113.md) | [(0.43)](/filings/0001746473-25-000175.md) | not reported | [(0.32)](/filings/0001746473-26-000090.md) | [(0.36)](/filings/0001746473-26-000113.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [57.7](/filings/0001746473-23-000074.md) | [63.2](/filings/0001746473-25-000054.md) | [114](/filings/0001746473-24-000076.md) | [80.4](/filings/0001746473-24-000145.md) | [79.6](/filings/0001746473-24-000171.md) | [71.2](/filings/0001746473-26-000037.md) | [91.9](/filings/0001746473-25-000099.md) | [86.8](/filings/0001746473-25-000150.md) | [93.7](/filings/0001746473-25-000175.md) | [45.4](/filings/0001746473-26-000113.md) | [22.2](/filings/0001746473-26-000090.md) | [24.9](/filings/0001746473-26-000113.md) |
| Current assets | $m | [534](/filings/0001746473-23-000074.md) | [506](/filings/0001746473-25-000054.md) | [490](/filings/0001746473-24-000076.md) | [448](/filings/0001746473-24-000145.md) | [410](/filings/0001746473-24-000171.md) | [362](/filings/0001746473-26-000037.md) | [311](/filings/0001746473-25-000099.md) | [267](/filings/0001746473-25-000150.md) | [246](/filings/0001746473-25-000175.md) | [196](/filings/0001746473-26-000113.md) | [175](/filings/0001746473-26-000090.md) | [163](/filings/0001746473-26-000113.md) |
| Total assets | $m | [540](/filings/0001746473-23-000074.md) | [512](/filings/0001746473-25-000054.md) | [522](/filings/0001746473-24-000076.md) | [484](/filings/0001746473-24-000145.md) | [446](/filings/0001746473-24-000171.md) | [397](/filings/0001746473-26-000037.md) | [345](/filings/0001746473-25-000099.md) | [300](/filings/0001746473-25-000150.md) | [277](/filings/0001746473-25-000175.md) | [225](/filings/0001746473-26-000113.md) | [203](/filings/0001746473-26-000090.md) | [190](/filings/0001746473-26-000113.md) |
| Current liabilities | $m | [27.4](/filings/0001746473-23-000074.md) | [28.5](/filings/0001746473-25-000054.md) | [30.4](/filings/0001746473-24-000076.md) | [30.9](/filings/0001746473-24-000145.md) | [40.0](/filings/0001746473-24-000171.md) | [33.2](/filings/0001746473-26-000037.md) | [28.2](/filings/0001746473-25-000099.md) | [20.6](/filings/0001746473-25-000150.md) | [17.6](/filings/0001746473-25-000175.md) | [16.4](/filings/0001746473-26-000113.md) | [10.4](/filings/0001746473-26-000090.md) | [16.5](/filings/0001746473-26-000113.md) |
| Total liabilities | $m | [37.4](/filings/0001746473-23-000074.md) | [38.6](/filings/0001746473-25-000054.md) | [84.3](/filings/0001746473-24-000076.md) | [91.1](/filings/0001746473-24-000145.md) | [99.8](/filings/0001746473-24-000171.md) | [92.9](/filings/0001746473-26-000037.md) | [87.6](/filings/0001746473-25-000099.md) | [79.7](/filings/0001746473-25-000150.md) | [76.3](/filings/0001746473-25-000175.md) | [44.0](/filings/0001746473-26-000113.md) | [37.4](/filings/0001746473-26-000090.md) | [43.0](/filings/0001746473-26-000113.md) |
| Long-term debt | $m | [10.0](/filings/0001746473-23-000074.md) | [10.1](/filings/0001746473-25-000054.md) | [30.0](/filings/0001746473-24-000076.md) | [30.1](/filings/0001746473-24-000145.md) | [30.1](/filings/0001746473-24-000171.md) | [30.2](/filings/0001746473-26-000037.md) | [30.3](/filings/0001746473-25-000099.md) | [30.4](/filings/0001746473-25-000150.md) | [30.4](/filings/0001746473-25-000175.md) | [0.0](/filings/0001746473-26-000113.md) | [0.0](/filings/0001746473-26-000090.md) | [0.0](/filings/0001746473-26-000113.md) |
| Shareholders' equity | $m | [503](/filings/0001746473-24-000171.md) | [474](/filings/0001746473-26-000037.md) | [437](/filings/0001746473-25-000175.md) | [393](/filings/0001746473-25-000175.md) | [346](/filings/0001746473-25-000175.md) | [304](/filings/0001746473-26-000113.md) | [257](/filings/0001746473-26-000113.md) | [220](/filings/0001746473-26-000113.md) | [200](/filings/0001746473-25-000175.md) | [181](/filings/0001746473-26-000113.md) | [165](/filings/0001746473-26-000113.md) | [147](/filings/0001746473-26-000113.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(36.2) d](/filings/0001746473-24-000171.md) | [(25.1) d](/filings/0001746473-25-000054.md) | [(30.3)](/filings/0001746473-25-000099.md) | [(45.3) d](/filings/0001746473-25-000150.md) | [(32.3) d](/filings/0001746473-25-000175.md) | [(47.7) d](/filings/0001746473-26-000037.md) | [(48.9)](/filings/0001746473-26-000090.md) | [(40.6) d](/filings/0001746473-26-000113.md) | [(21.1) d](/filings/0001746473-25-000175.md) | [(17.8) d](/filings/0001746473-26-000037.md) | [(19.2)](/filings/0001746473-26-000090.md) | [(12.8) d](/filings/0001746473-26-000113.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001746473-24-000171.md) | [0.1 d](/filings/0001746473-25-000054.md) | [1.5](/filings/0001746473-25-000099.md) | [1.3 d](/filings/0001746473-25-000150.md) | [0.9 d](/filings/0001746473-25-000175.md) | [0.2 d](/filings/0001746473-26-000037.md) | [0.3](/filings/0001746473-26-000090.md) | [0.1 d](/filings/0001746473-26-000113.md) | [0.0 d](/filings/0001746473-25-000175.md) | [0.0 d](/filings/0001746473-26-000037.md) | [0.0](/filings/0001746473-26-000090.md) | [0.0 d](/filings/0001746473-26-000113.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [46.8](/filings/0001746473-23-000074.md) | [56.1](/filings/0001746473-24-000076.md) | [59.2](/filings/0001746473-24-000145.md) | [59.7](/filings/0001746473-24-000171.md) | [60.2](/filings/0001746473-25-000099.md) | [60.4](/filings/0001746473-25-000150.md) | [60.7](/filings/0001746473-25-000175.md) | [61.2](/filings/0001746473-26-000090.md) | [61.4](/filings/0001746473-26-000113.md) | [61.4](/filings/0001746473-25-000175.md) | [61.8](/filings/0001746473-26-000090.md) | [61.9](/filings/0001746473-26-000113.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 61,921,897 at 2026-08-07, from the cover of the [10-Q filed 2026-08-11](/filings/0001746473-26-000113.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.